161 results about "Glaucoma present" patented technology

According to the glaucoma multi-mode auxiliary diagnosis device and the electronic equipment, firstly, first feature extraction and second feature extraction are carried out on an eye fundus image and an OCT image respectively, then semantic spaces of an eye fundus image mode and an OCT image mode are aligned by utilizing comparison loss, and the first feature and the second feature are fused by utilizing a cross attention mechanism, so that an eye fundus image is obtained. According to the method, the two modal data are subjected to fusion to obtain fusion features, then the fusion features are subjected to feature extraction to obtain third features, and glaucoma classification judgment is performed based on the third features, so that global modeling of the two modal data can be realized, effective features are extracted to perform glaucoma classification judgment, and the accuracy and timeliness of diagnosis are ensured.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention relates to the technical field of glaucoma grading, and discloses a glaucoma grading system based on multi-modal conditional state space fusion, which comprises the following steps: acquiring a CFP image and an OCT image, and constructing a glaucoma grading network model which comprises a circular structure perception attention module, a layer prior enhancement axial attention module and a conditional state space fusion module; the circular structure perception attention module enhances the characterization capability of a circular key pathological change area in the CFP image, and the layer prior enhancement axial attention module enhances the utilization of key pathological change information in the OCT image; and the conditional state space fusion module dynamically modulates CFP spatial features through OCT global information, realizes cross-modal feature interaction, and performs glaucoma grading by using a trained network model. According to the method, multi-modal information can be effectively fused, the feature extraction capability of glaucoma related pathological features is enhanced, and the glaucoma grading performance is improved.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

An adjustable flow glaucoma diverter is disclosed herein. For example, in one embodiment, an adjustable flow diverter may include an outflow drainage tube having a proximal inflow region and a distal outflow region. The proximal inflow region may include an aperture defining a fluid inlet range disposed at a location allowing fluid to flow therethrough. The diverter also includes an inflow control assembly located at the proximal inflow region. The inflow control assembly may include a control element configured to slidably mate with the proximal inflow region and a spring element. The spring element is configured to be activated by non-invasive energy and, upon activation, slidably move the control element along the proximal inflow region such that (a) the one or more apertures are accessible and have a first fluid flow cross-section, or (b) the one or more apertures are at least partially covered by the control element and have a second, different fluid flow cross-section.

The present disclosure describes an optical probe for applying a laser light to at least the flat portion of the ciliary body and optionally other areas, such as the trabecular mesh, the ciliary crown and / or the ciliary sulcus of the eye, the present invention relates to methods, such as for treating glaucoma, reducing intraocular pressure (IOP), improving the outflow of aqueous humor from the eye, and / or reducing the accumulation of aqueous humor within the eye. The optical probe may be adapted for simultaneous treatment of a plurality of different regions, tissues, or eye bodies of the eye, or for sequential treatment of a plurality of different regions, tissues, or eye bodies of the eye.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

Provided herein are solid forms, e.g., polymorphs, of 2-(3-((7R,8aS)-7-fluorohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azetidin-3-yl)acetonitrile, which are useful for treating kinase-related diseases or disorders. The solid forms, and compositions thereof, are useful for treating diseases in a subject, including, but not limited to, ocular diseases such as glaucoma, ocular hypertension, ocular wound repair, neurodegenerative ocular diseases, retinal detachment, and non-ocular diseases such as nerve injury, or skin wound repair, or inflammatory diseases, among others. (Compound 1) TIFF2026501674000028.tif4839

The present disclosure provides compositions comprising at least one compound of Formula (I), suitable for application to the ocular surface. The present disclosure also provides methods of making compositions comprising at least one compound of Formula (I). The present disclosure further provides methods of using compositions comprising at least one compound of Formula (I) to reduce intraocular pressure, provide neuroprotection, and / or treat ocular conditions such as glaucoma.

The utility model relates to a glaucoma drainage tube with double drainage discs, which belongs to the technical field of medical artificial implants and comprises a drainage tube body, a drainage mechanism is arranged on the right side of the drainage tube body and comprises a fixing structure fixedly mounted on the outer side of the drainage tube, and the double-layer drainage discs are fixedly mounted on the right side of the fixing structure. The glaucoma drainage tube with the double drainage discs can be easily implanted into an anterior chamber corner during an operation, can be accurately butted with an aqueous fluid generation source, ensures that aqueous fluid flows in without hindrance, lays a solid foundation for subsequent drainage, can be tightly attached to a sclera by virtue of the characteristics of the fixing structure, greatly reduces the displacement risk of an implant, ensures stable operation of a whole drainage system, and has a good application prospect. The upper drainage disc and the lower drainage disc cooperatively operate, the conjunctival sac is accurately opened, a stable filtering bubble is formed, the drainage groove matched with the drainage tube body in the drainage tube forms a smooth aqueous humor channel, aqueous humor drainage is accelerated, the supporting structure efficiently promotes aqueous humor diffusion between the two layers of drainage discs, and the drainage efficiency is comprehensively optimized.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.

The present application relates to a kind of molecular markers for early diagnosis of glaucoma, the molecular marker is tsRNA, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC.The present application finds that relative to healthy control group, the expression of tsRNA-5009b-ValCAC in POAG group patient is significantly down-regulated, its AUC value in ROC curve is 0.717, and diagnosis performance is good, indicating that the tsRNAs can be used as early diagnosis of POAG molecular marker and applied to clinical.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

The present disclosure relates to a drug delivery system comprising an intraocular pressure-lowering agent, a neurotrophic agent such as a CNTF compound, a C-type natriuretic peptide (CNP) compound, a Tie-2 agonist, a natriuretic peptide receptor B (NPR-B) compound, or an apoptosis signaling fragmentation inhibitor (FAS) or FAS ligand (FASL) inhibitor (including any combination of these compounds), and a sustained-delivery component. Methods, medicaments, kits, methods of use, and methods of manufacture for treating glaucoma or related conditions are also disclosed. [Selection diagram] None

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

The invention provides an angle rotation expansion type electrocoagulation trabecular incision knife for glaucoma surgery, and relates to the field of trabecular incision knives. The high-frequency electrotome comprises a knife handle, a high-frequency electrotome host, a connecting wire and a negative plate, the electric knife is characterized in that a conductive mechanism is arranged in the knife handle; the conductive mechanism is electrically connected with the positive electrode of the high-frequency electrotome main machine through a connecting wire; an adjusting mechanism is arranged at the lower end of the cutter handle; a cutting mechanism is arranged at the end, away from the cutter handle, of the adjusting mechanism. The outer side of the cutting mechanism is sleeved with a sleeve rod. Through mutual cooperation of a conductive wire, a cutting knife, a negative plate and other mechanisms, after the conductive wire electrifies the cutting knife, the positive electrode of the cutting knife is in contact with the negative electrode of the negative plate when the cutting knife carries out surgical cutting on a patient lying on the negative plate, and then a wound is burnt, blood is coagulated, and the wound is prevented from being damaged. The problem that bleeding of a patient blocks medical staff is solved, and the operation safety is improved.

The present invention relates to an ophthalmic ultrasonic emulsification sleeve for confirming intraocular and extraocular penetration and perfusion, which allows determining whether aqueous humor communication between the inside and outside of the eye is smooth through a microtube implanted in the eye during glaucoma tube surgery. The sleeve is characterized by having a rigid branch tube made of a material harder than a sleeve made of a soft material, provided in a perfusion port that allows the injection of a balance salt solution into the eye, and with the branch tube connected to the perfusion port, the tip of the branch tube protrudes further than the tip of the Paco tip, and the end of the microtube inside the eye is connected to the tip of the branch tube, so that the establishment of aqueous humor communication of the microtube can be quickly and accurately and sensorially confirmed based on the pattern of pressure change in the conjunctival area and surrounding blood flow change that occurs when the balance salt solution leaks out of the eye.

Disclosed is a glaucoma device (10, 1010) comprising: an implant body (15, 1015) including an anterior portion (20, 1020), a distal portion (35, 1035), a plurality of arms (40, 1040) extending between the anterior portion (20, 1020) and the distal portion (35, 1035) to provide connection therebetween; and a fluid network extending from the anterior portion (20, 1020) along at least one of the arms (40, 1040) to the distal portion (35, 1035), the fluid network providing a plurality of outlet channels (90, 1090) for fluid exit therefrom; and a fluid inlet cannula (30, 1030) arranged on the anterior portion (20, 1020) of the implant body (15, 1015) and adapted for fluid connection with ocular tissue.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The utility model discloses a novel microforceps relates to forceps technical field. The novel microforceps includes two opposite setting's tongs arm, clamping surface, connecting structure and antiskid structure, clamping surface is set respectively in two tongs arm's front end, when two clamping surface is close, forms the clamping portion for clamping glaucoma gel drainage tube, connecting structure is connected in two tongs arm's rear end, antiskid structure sets up on clamping surface. The novel microforceps passes through the friction of clamping surface enhancement, has effectively reduced the phenomenon of slipping in the clamping process, thereby makes the drainage tube can be clamped more stably, and smoothly adjusts its position, has guaranteed the smooth operation of the operation process.

The current invention relates to a retainer provided with an annular intraocular drug delivery device for use in the treatment of glaucoma, said annular intraocular drug delivery device for use in the treatment of glaucoma having an inner circumference and an outer circumference, said retainer comprising: a retainer body at least partially closed off by a retainer cap, said retainer cap being configured to support said annular intraocular drug delivery device for use in the treatment of glaucoma, and a retainer slider, being displaceable perpendicular to the longitudinal axis of the retainer body, characterized in, that said retainer cap at least supports said inner circumference of said annular intraocular drug delivery device for use in the treatment of glaucoma.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.